PROSPER

What is PROSPER?

Every 40 seconds, someone in the U.S. has a stroke, with almost ¼ of these being recurrent strokes. The prognosis after stroke remains poor, with 1-year mortality rate of 15-30%. To date, many questions remain unanswered for real-world stroke survivors on what therapies will have the greatest impact on their well-being.

PROSPER is a national, sustainable model to improve decision-making and patient-centered stroke outcomes through comparative effectiveness research. Using Get With The Guidelines^®- Stroke data linked with Medicare claims, we will evaluate outcomes prioritized by stroke survivor focus groups and surveys in 3 therapeutic areas:

anticoagulation
statin therapy, and
anti-depressant therapy.

PROSPER's primary outcome for these 3 areas summarizes the "Home-time" (days alive and well outside of an institution) which is what patients believe are the most important factors to them:

being independent, and
without significant health problems.

Other selected outcomes to be evaluated include recurrent stroke, mortality and readmission. Patient-reported outcomes selected by our stakeholders include:

quality of life
depression
functional status and fatigue.

The knowledge gained from this work will inform the development of novel tools to empower stroke survivors to more effectively make treatment decisions regarding their stroke care.